Monday, February 27, 2012

One-on-One with Joe Belanoff of Corcept Therapeutics

Corcept Therapeutics Inc.’s Korlym is no Lipitor, and that suits CEO Dr. Joe Belanoff just fine for now.
While Vivus Inc.’s recently approved obesity drug Qnexa inspired talk that it would be a blockbuster like weight-loss drug Lipitor, Menlo Park-based Corcept’s Korlym won approval Feb. 17 for a drug aimed at roughly 5,000 to 10,000 patients with Cushing’s syndrome. That's a mere fraction of Qnexa's potential market.
Belanoff spoke with me recently about Corcept, its strategy for Korlym and how he celebrated Korlym’s approval, which earned him a $481,097 bonus.

No comments:

Post a Comment